Search research articles
Contact Us
Filters
Showing results (111-120 of 145) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017
Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
Oncotarget
|
November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
Selma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"
Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
The Journal of Allergy and Clinical Immunology
|
April 12, 2026
Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group
Joana Calvão, Adèle de Masson, Antonio Cozzio, et al.
European Journal of Dermatology : EJD
|
May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs
Martine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Claus Garbe, Ulrike Keim, Stefan Suciu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection
Daniëlle Verver, A Rekkas, Claus Garbe, et al.
Arthritis Research & Therapy
|
October 25, 2011
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features
Rudolf Mierau, Pia Moinzadeh, Gabriela Riemekasten, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 145) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017
Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
Oncotarget
|
November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
Selma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"
Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
The Journal of Allergy and Clinical Immunology
|
April 12, 2026
Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group
Joana Calvão, Adèle de Masson, Antonio Cozzio, et al.
European Journal of Dermatology : EJD
|
May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs
Martine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Claus Garbe, Ulrike Keim, Stefan Suciu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection
Daniëlle Verver, A Rekkas, Claus Garbe, et al.
Arthritis Research & Therapy
|
October 25, 2011
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features
Rudolf Mierau, Pia Moinzadeh, Gabriela Riemekasten, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Page
of 15